Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2024-11-04 Regulatory Filings
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 4, 2024. It announces positive feedback from an FDA end-of-Phase 2 meeting and details about a conference call and presentation slides. The document includes a press release and a slide presentation as exhibits. It does not contain full financial statements or detailed financial analysis but rather regulatory and event disclosures. The document is not an earnings release, annual report, or interim report. It is a regulatory announcement about a clinical trial update and related investor communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2024-11-04 English
Regulatory Filings 2024
Regulatory Filings
2024-11-01 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 25, 2024. It reports a Regulation FD Disclosure about a press release announcing clinical trial data presented at a medical conference. The document includes no financial statements or detailed financial analysis but rather a disclosure of clinical trial results and a press release. The Form 8-K is a regulatory filing used to report unscheduled material events or corporate changes. Given the nature of the content and the form type, this is a Regulatory Filing (RNS) rather than a financial report or other specific category.
2024-10-25 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-10-24 English
4
Director's Dealing
2024-10-03 English
4
Director's Dealing
2024-09-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.